DE69418322D1 - Analoge für spezifische oligosaccharid-protein-wechselwirkungen und ihre verwendungen - Google Patents

Analoge für spezifische oligosaccharid-protein-wechselwirkungen und ihre verwendungen

Info

Publication number
DE69418322D1
DE69418322D1 DE69418322T DE69418322T DE69418322D1 DE 69418322 D1 DE69418322 D1 DE 69418322D1 DE 69418322 T DE69418322 T DE 69418322T DE 69418322 T DE69418322 T DE 69418322T DE 69418322 D1 DE69418322 D1 DE 69418322D1
Authority
DE
Germany
Prior art keywords
specific
methods
compositions
oligosaccharid
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69418322T
Other languages
English (en)
Inventor
Daniel Witt
Walter Herlihy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycan Pharmaceuticals Inc
Original Assignee
Glycan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycan Pharmaceuticals Inc filed Critical Glycan Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69418322D1 publication Critical patent/DE69418322D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69418322T 1993-03-01 1994-02-28 Analoge für spezifische oligosaccharid-protein-wechselwirkungen und ihre verwendungen Expired - Lifetime DE69418322D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2455893A 1993-03-01 1993-03-01
PCT/US1994/002051 WO1994020512A2 (en) 1993-03-01 1994-02-28 Analogs for specific oligosaccharide-protein interactions and uses therefor

Publications (1)

Publication Number Publication Date
DE69418322D1 true DE69418322D1 (de) 1999-06-10

Family

ID=21821208

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69418322T Expired - Lifetime DE69418322D1 (de) 1993-03-01 1994-02-28 Analoge für spezifische oligosaccharid-protein-wechselwirkungen und ihre verwendungen

Country Status (7)

Country Link
US (1) US5795860A (de)
EP (2) EP0688327B1 (de)
AT (1) ATE179712T1 (de)
AU (1) AU6353294A (de)
CA (1) CA2157388C (de)
DE (1) DE69418322D1 (de)
WO (1) WO1994020512A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264709B1 (it) * 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
US6277874B1 (en) * 1996-07-09 2001-08-21 University Of Cincinnati And Apologic, Incorporated Methods for the treatment of apolipoprotein E related diseases
US6245751B1 (en) 1996-07-09 2001-06-12 University Of Cincinnati Methods for the treatment of apolipoprotein E related diseases
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6399078B1 (en) * 1998-06-01 2002-06-04 University Of Maryland Biotechnology Institute Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
GB9913415D0 (en) * 1999-06-10 1999-08-11 Central Manchester Healthcare Heparanase assay
US6472436B1 (en) * 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
DE60141992D1 (de) * 2000-09-05 2010-06-10 Biosight Ltd
US8314060B2 (en) * 2000-09-05 2012-11-20 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
AU2002351576A1 (en) * 2001-12-13 2003-07-09 Ism Biopolymer Inc. Method of modulating release of saccharides and uses thereof
CH696701A5 (de) 2001-12-18 2007-10-15 Hoffmann La Roche Verfahren zum Testen eines Mittels auf dessen Fähigkeit, die Heparanaseaktivität zu hemmen.
DE10258770B4 (de) * 2001-12-18 2005-02-10 F. Hoffmann-La Roche Ag Verfahren zum Testen eines Mittels auf dessen Fähigkeit, die Heparanaseaktivität zu hemmen
GB0216861D0 (en) * 2002-07-19 2002-08-28 Univ Birmingham Saccharide libraries
EP1634075B1 (de) * 2003-06-10 2015-01-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Elektronische Vorrichtung zur Kommunikation mit lebenden Zellen
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826827A (en) * 1979-10-05 1989-05-02 Choay S.A. Short chained oligosaccharides having biological properties, a process for making the same and the use thereof as drugs
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
EP0337327A1 (de) * 1988-04-09 1989-10-18 Bioiberica, S.A. Verfahren zur Herstellung von neuen Oligosaccharid-Fragmenten durch kontrollierte chemische Depolymerisation von Heparin
EP0361960A3 (de) * 1988-09-29 1992-01-02 RANNEY, David F. Verfahren und Vorrichtung zur Bilderzeugung mittels magnetischer Resonanz
US5380716A (en) * 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
JPH04506066A (ja) * 1989-06-16 1992-10-22 ジ・アップジョン・カンパニー 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5116483A (en) * 1989-11-06 1992-05-26 Massachusetts Institute Of Technology Comb for affinity co-electrophoresis
US5079228A (en) * 1990-02-05 1992-01-07 Board Of Regents, The University Of Texas System Peptide inhibitors of neutrophil activating factor induced chemotaxis
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
AU7478191A (en) * 1990-03-05 1991-10-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Endogenous, suramin-induced, sulfated glycosaminoglycans as anti-cancer agents in humans
ES2060284T3 (es) * 1990-04-23 1994-11-16 Sanofi Elf Un procedimiento para la preparacion de un derivado de carbohidrato que comprende una unidad de trisacarido.
WO1991019501A1 (en) * 1990-06-15 1991-12-26 Cytel Corporation Intercellular adhesion mediators
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5166137A (en) * 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
MX9201801A (es) * 1991-04-16 1992-10-30 Seikagaku Kogyo Co Ltd Oligosacarido que tiene afinidad para el factor de desarrollo del fibroplasto y procedimiento para producirlo.
EP0509120B1 (de) * 1991-04-18 1996-07-17 LABORATORI BALDACCI Spa Topische Anwendung von Glycosaminoglykane zur Prävention und Behandlung der Zervikal- oder Vaginalerkrankungen
US5807982A (en) * 1991-04-29 1998-09-15 Cornell Research Foundation, Inc. Affinity purified heparin
IL102758A (en) * 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
AU2790892A (en) * 1991-10-23 1993-05-21 British Technology Group Limited Use of suramine and related compounds as contraceptive agents
JPH07504886A (ja) * 1991-11-14 1995-06-01 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション 細胞調節因子のインヒビターおよびはん痕形成を予防または緩和する方法
EP0636175A1 (de) * 1992-04-03 1995-02-01 La Jolla Cancer Research Foundation Decorin-fragmente und verfahren zur zell-regulationfaktoren-inhibierung

Also Published As

Publication number Publication date
EP0688327A1 (de) 1995-12-27
EP0900804A2 (de) 1999-03-10
WO1994020512A2 (en) 1994-09-15
CA2157388A1 (en) 1994-09-15
WO1994020512A3 (en) 1994-11-24
US5795860A (en) 1998-08-18
EP0688327B1 (de) 1999-05-06
AU6353294A (en) 1994-09-26
CA2157388C (en) 1998-12-15
ATE179712T1 (de) 1999-05-15

Similar Documents

Publication Publication Date Title
DE69418322D1 (de) Analoge für spezifische oligosaccharid-protein-wechselwirkungen und ihre verwendungen
ATE262037T1 (de) Modifizierte liganden für den tie-2-rezeptor
ATE239079T1 (de) Gewebeinhibitor für metalloproteasen type 3 (timp-3)
ATE302278T1 (de) Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen
DE68922065T2 (de) Verbesserte Packung für chirurgisches Nahtmaterial.
ATE315654T1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
DE69316948T2 (de) Lösliche Liganden für CD40
ES2153671T3 (es) Peptidos neuroactivos.
NO178665C (no) Fosfopeptider og sammensetning for kosmetiske formål
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
MXPA02008239A (es) Gen humano de la esquizofrenia.
DE69811348D1 (de) Verfahren zur modulierung des wachstums kollateraler arterien und / oder anderer arterien aus bestehenden arteriolen verbindungen
DE69426076D1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
NO175313C (no) Joderte polymerer og deres anvendelse
DE3751218T2 (de) Verfahren und therapeutische Zubereitungen für die Behandlung von Gerinnungsstörungen.
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
KR950702207A (ko) Tlp 복합체에 대한 항원성 부위와 이의 항체(antigenic regions of tumour-liberated particles (tlp) complexes and antibodies against them)
DE59005898D1 (de) Dinatriumsalz des Trimercapto-s-triazin-hexahydrats, Verfahren zu seiner Herstellung und Verwendung.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE69929683D1 (de) Antisense modulierung von lfa-3
ATE26109T1 (de) Acetylcystein-salze, ihre herstellung und verwendung.
WO1999050671A3 (en) Toso as a target for drug screening

Legal Events

Date Code Title Description
8332 No legal effect for de